HopeStage
Back to all studies
WithdrawnNCT05481112

Assessing Optimal XR-Buprenorphine Initiation Points in Jail

Medication studyAges 18–65United StatesAddiction
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 65 years.

Listed locations
New YorkSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateEstimated: November 1, 2023
Recruitment status
Withdrawn
Enrollment listed in the registry
0
Sponsor
NYU Langone Health
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT05481112
Official title
Show the full official title

Assessing Optimal XR-Buprenorphine Initiation Points in Jail

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Withdrawn

New York

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is NYU Langone Health.

Does this study involve medication?

Yes. The study involves medication, including Extended-Release Buprenorphine Injection.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as withdrawn.

Want to explore more studies?

Explore studies